Volume 25, Issue 109, March, 2021

Topical Minocycline as treatment for Acne Vulgaris

Firas Fakhir Altameemi^1♦, Oday Sajjad Alsawad²

¹Department of Dermatology & Venereology, Alsadr teaching hospital, Basra, Iraq
²College of pharmacy, University of Basrah, Basra, Iraq

^♦Corresponding author
Department of Dermatology & Venereology, Alsadr teaching hospital, Basra, Iraq; Email: uday_sajad@yahoo.com

ABSTRACT

Objective: Evaluate the efficacy and safety of 4% topical minocycline in treating moderate-to-severe acne vulgaris (AV). Methods: A prospective single arm clinical study than involved 50 patients with moderate-to-severe acne, the patients were followed up for 12 weeks from baseline and was give once daily minocycline 4% topical treatment. The coprimary end points at week 12 were the absolute change in inflammatory lesion counts from baseline and the rates of Investigator’s Global Assessment (IGA)-assessed treatment success, which was defined as an IGA score of 0 or 1 (description of clear or almost clear) plus at least a 2-grade improvement from baseline. Other end points included the absolute change from baseline in noninflammatory lesion count at week 12. Results: The study included 50 patients with moderate – severe lesions (4:1 ratio), with the majority female participants, mean age was 21.5 ± 4.7 years. In the present study there was significant reduction in both mean count of inflammatory and non-inflammatory lesions after 12 weeks of follow-up (-27.5 and -30, respectively) with 16% of the patients achieved treatment success according to IGA score. Conclusions: The once daily use of topical minocycline 4% for 12 weeks result in improvement in both inflammatory and non-inflammatory lesion, and improvement in investigator global assessment. In term of safety this product offers very few adverse events.

Keywords: minocycline, topical, inflammatory lesions, non-inflammatory lesions

Medical Science, 2021, 25(109), 730-734

PDF